Anti-Muc1 Car-T Cells
Malignant Glioma of Brain
PersonGen BioTherapeutics (Suzhou) Co., Ltd.Cell therapyPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
8 Active assets in the Malignant Glioma of Brain cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FDOPA University of Alberta | Phase 3 | B |
Everolimus St. Joseph's Hospital and Medical Center, Phoenix | Phase 1 | B |
Ribociclib St. Joseph's Hospital and Medical Center, Phoenix | Phase 1 | B |
Ganciclovir Huazhong University of Science and Technology | Phase 2 | B |
Adv-Tk Huazhong University of Science and Technology | Phase 2 | B |
View all 23 →
Same molecule, other indications
Anti-Muc1 Car-T Cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →